Ibrigampar

DB05490InvestigationalSmall molecule

AMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin. T131 is a selective modulator... T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin.

Mechanism: T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin. T131 is not structurally related to the thiazolidinedione class of PPARg agonists, which includes Actos and Avandia
Curator reviewed
Primary indication: Investigated for use/treatment in diabetes mellitus type 2.Curator reviewed
Formula / weight: C₂₁H₁₂Cl₄N₂O₃S · 514.209 g/mol (avg)
Code names: AMG-131 · INT-131 · T-0903131 · T131

Resolves to

Compound

UNIIE7ILQ6U50JCAS315224-26-1ChEMBLCHEMBL1236924PubChem16145453

Structure

InChIKeyNMRWDFUZLLQSBN-UHFFFAOYSA-NSMILESClC1=CC=C(C(Cl)=C1)S(=O)(=O)NC1=CC(Cl)=C(OC2=CN=C3C=CC=CC3=C2)C(Cl)=C1

Targets

P37231PPARG

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ibrigampar, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account